Albert David launches new products, to enter new segments soon

K P Mundhra Executive Director, Albert David

Kolkata-based pharma company Albert David, a unit of the Kothari group, has recently undertaken a range of initiatives for development of new products for increasing its market share in formulation segment to achieve sustained growth in the current fiscal year.

“In the current fiscal, we have introduced new products and would be soon adding more brands to expand our product offerings,” said Kamal Prasad Mundhra, Executive Director, Albert David.

Albert David, which makes pharma formulations, bulk drugs and injections, has three manufacturing plants — in Kolkata (for tablets and powder, small volume parenterals, oral liquids, bulk drugs), Ghaziabad (for IV fluids in glass and polythene containers) and Mandideep (disposable syringes & needles).

In the last fiscal, the company, touched a turnover of Rs 230 crore.

The company has successfully launched UDCA and Silymarin combination, ‘Actimarin’ (75mg and 150 mg) /Actimarin Forte’, Febuxostat – ‘FBX’, Dapoxetin – ‘Amjoy’, a drug for premature ejaculation and has also introduced products like ‘Anaflam TH4 / TH 8’ – a skeletal muscle relaxant, ‘L-Arginine’ Sachets, Isoxsuprine tablets and Alamin RG / RGX, which it feels will tilt the balance in its favour.

Soon, it would launch betahistine and domperidone combination, hormonal preparations and anti-asthmatic drugs.

Commenting on its 55-year old flagship product, ‘Placentrex’, Mundhra brushed aside any apprehension about the product.

Earlier, the Government of India pursuant to the directives of the Hon’ble High Court of Delhi had revoked the ban on ‘Placentrex Injection’ for PID and Placentrex topical application for wound healing. This led to some confusion among the medical fraternity but the issue has been resolved and all out efforts have been made to restore the confidence of the doctors and revive the brand, he added.

He said, “The company has given much thrust on its Research & Development initiatives. The R&D wing is involved in the development of newer products with maximum therapeutic values, while at the same time focusing on improving the quality of its existing products.”

In the coming days, the company plans to tap the international market in a bigger way. Exports will remain to be a key driver for growth of the company in the coming years, Mundhra added.

He exulted confidence about the prospects of the pharma industry in the country and said, ‘Albert David will continue to grow with the current strategies in place and is equipped to meet any future challenges.’

EP Team – Kolkata